PRWeb The Leader Press Release Distribution

We're here to help 1-866-640-6397

Login Create Free Account


All Press Releases for February 13, 2007 Subscribe to this News Feed    
 

Cedarburg Pharmaceuticals Raises $3.5 Million in Series A-3 Financing

Cedarburg Pharmaceuticals received $3.5 million in preferred stock financing. Investors included Sanders Morris Harris Group and Alfred Bader, founder of Aldrich Chemical. In addition, Cedarburg received European approval to market cancer pain relievers Fentanyl Base and Fentanyl Citrate.

Grafton, WI (PRWEB) February 13, 2007 -- Cedarburg Pharmaceuticals, Inc., a drug process development and API provider, today announced that it has raised a total of $3.5 million in the company's Series A-3 (fourth round) of preferred stock financing.

Participants in the latest round include asset management company Sanders Morris Harris Group and Alfred Bader, founder of Aldrich Chemical (now Sigma Aldrich). Cedarburg has raised $18.8 million to date since its founding in 1997.

This new round of investment demonstrates tremendous confidence for Cedarburg's ability to bring value to the marketplace in the form of making the drug development and scale up process easier for our customers
"This new round of investment demonstrates tremendous confidence for Cedarburg's ability to bring value to the marketplace in the form of making the drug development and scale up process easier for our customers" said Thomas Groble, Chief Operating Officer of Cedarburg. "The funding will be used primarily to expand our capabilities to meet the needs of virtual pharma companies".

Cedarburg recently received European approval to market cancer pain relievers Fentanyl Base and Fentanyl Citrate. The company holds Drug Master Files for both Fentanyl compounds in the U.S. as well as DEA Schedule I through V licenses and permits for controlled substances.

About Cedarburg Pharmaceuticals
Cedarburg Pharmaceuticals is a value-driven commercial and clinical API provider. We define value as making life simpler for our customers. That means understanding our customers' needs and exceeding their expectations through transparent project management and resourcefully applying our expertise in process development, validation, scale-up and analytical method development. Backed by full cGMP compliance and QA oversight, our experience and flexibility enable us to succeed where others fail. For more information, please visit us online at www.cedarburgpharma.com.

###

Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/VGhpci1TcXVhLVBpZ2ctSG9yci1NYWduLVplcm8=

Technorati Tags

Bookmark -  Del.icio.us | Furl It | Technorati | Ask | MyWeb | Propeller | Live Bookmarks | Newsvine | TailRank | Reddit | Slashdot | Digg | Stumbleupon | Google Bookmarks | Sphere | Blink It | Spurl


OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareThis
CONTACT INFORMATION
Kenneth Li
Cedarburg Pharmaceuticals Inc.
312-375-1157
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your PRWeb News Management Console.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these release. Our complete disclaimer appearshere.
 
Close Move